Lipocine
LPCNLPCN · Stock Price
Historical price data
Overview
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative oral therapeutics for metabolic and endocrine disorders. Its core strategy leverages a proprietary solubilization technology (Lip'ral) to reposition established drug molecules with poor water solubility into convenient oral formulations, thereby improving patient compliance. Key achievements include the FDA approval of its oral testosterone replacement therapy, TLANDO®, and the advancement of a diversified pipeline targeting high-need areas like NASH and postpartum depression through the efficient 505(b)(2) regulatory pathway. The company's mission is to enhance health outcomes by overcoming the challenge of oral drug absorption for hydrophobic compounds.
Technology Platform
Lip'ral solubilization technology for the effective oral delivery of water-insoluble (hydrophobic) drugs, enabling convenient oral formulations of compounds like steroids and hormones.
Pipeline
8| Drug | Indication | Stage | Watch |
|---|---|---|---|
| LPCN 1021 | Hypogonadism, Male | Phase 3 | |
| LPCN 1154A + Placebo | Depression, Postpartum | Phase 3 | |
| LPCN 1021 | Hypogonadism, Male | Phase 3 | |
| Oral testosterone undecanoate, LPCN 1021 + Topical testoster... | Male Hypogonadism | Phase 3 | |
| LPCN 1021 | Hypogonadism, Male | Phase 3 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Lipocine competes in crowded markets but uses its oral delivery platform for differentiation: TLANDO is the only oral TRT without titration vs. gels/injectables; LPCN 1154 will compete with oral zuranolone in PPD; and its NASH strategy targets a specific subpopulation (hypogonadal men) to avoid direct competition with broader-acting agents from large pharma.